CDC- BRFSS – ACBS 2022 Adult Prevalence Table 7

Table 7: Estimated percent using an inhaled corticosteroid in the past 3 months among adults1 with current2 asthma status by state/territory – BRFSS Asthma Call-back Survey, United States, 2022.
State/Territory Current
Sample
size±
% SE§ 95% CI
Arizona 328 23.0 3.7 (15.7 – 30.3)
California 307 21.5 3.2 (15.2 – 27.8)
Connecticut 490 34.4 3.2 (28.1 – 40.7)
Florida 449 26.0 4.2 (17.8 – 34.2)
Georgia 329 33.6 4.5 (24.8 – 42.4)
Hawaii 204 27.4 5.0 (17.6 – 37.2)
Indiana 474 28.2 2.6 (23.1 – 33.3)
Iowa 287 35.3 3.8 (27.9 – 42.7)
Kansas 233 29.3 4.2 (21.1 – 37.5)
Maine 351 28.4 3.8 (21.0 – 35.8)
Maryland 387 32.1 3.8 (24.7 – 39.5)
Massachusetts 328 34.9 3.8 (27.5 – 42.3)
Michigan 502 29.3 2.6 (24.2 – 34.4)
Minnesota 539 30.5 2.8 (25.0 – 36.0)
Missouri 237 30.3 4.2 (22.1 – 38.5)
Nebraska 158 26.3 4.6 (17.3 – 35.3)
New Hampshire 379 29.2 3.3 (22.7 – 35.7)
New Jersey 296 37.6 3.8 (30.2 – 45.0)
New Mexico 158 30.9 5.3 (20.5 – 41.3)
New York 314 29.2 3.4 (22.5 – 35.9)
Ohio 405 26.3 3.2 (20.0 – 32.6)
Oregon 139 22.5 4.8 (13.1 – 31.9)
Rhode Island 237 37.6 4.2 (29.4 – 45.8)
Texas 279 23.6 3.8 (16.2 – 31.0)
Utah 308 29.2 3.5 (22.3 – 36.1)
Vermont 498 31.6 2.6 (26.5 – 36.7)
Wisconsin 395 30.2 3.0 (24.3 – 36.1)
Puerto Rico 260 21.0 3.4 (14.3 – 27.7)
28 States / Area 9,271 27.8 1.0 (25.8 – 29.8)
Median 29.3
Range 21.0-37.6

1 Aged ≥ 18 years

2 “Yes” response to “Do you still have asthma?”

± Sample size for adults with current asthma, excludes “DK/Refused”

§ Standard error

Confidence interval

Link for Summary Data Quality Report: https://www.cdc.gov/brfss/acbs/2022/pdf/sdq_report_acbs_22-508.pdf